SG11201500234YA - Process for making isoquinoline compounds - Google Patents

Process for making isoquinoline compounds

Info

Publication number
SG11201500234YA
SG11201500234YA SG11201500234YA SG11201500234YA SG11201500234YA SG 11201500234Y A SG11201500234Y A SG 11201500234YA SG 11201500234Y A SG11201500234Y A SG 11201500234YA SG 11201500234Y A SG11201500234Y A SG 11201500234YA SG 11201500234Y A SG11201500234Y A SG 11201500234YA
Authority
SG
Singapore
Prior art keywords
isoquinoline compounds
making
making isoquinoline
compounds
isoquinoline
Prior art date
Application number
SG11201500234YA
Other languages
English (en)
Inventor
Michael D Thompson
Jung Min Park
Michael P Arend
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48857024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201500234Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of SG11201500234YA publication Critical patent/SG11201500234YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Epidemiology (AREA)
SG11201500234YA 2012-07-16 2013-07-15 Process for making isoquinoline compounds SG11201500234YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261672191P 2012-07-16 2012-07-16
PCT/US2013/050538 WO2014014834A1 (en) 2012-07-16 2013-07-15 Process for making isoquinoline compounds

Publications (1)

Publication Number Publication Date
SG11201500234YA true SG11201500234YA (en) 2015-02-27

Family

ID=48857024

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201500234YA SG11201500234YA (en) 2012-07-16 2013-07-15 Process for making isoquinoline compounds

Country Status (22)

Country Link
US (2) US9340511B2 (https=)
EP (2) EP2872487B1 (https=)
JP (1) JP6196671B2 (https=)
KR (1) KR102145272B1 (https=)
CN (2) CN106083719B (https=)
AU (1) AU2013290437B2 (https=)
BR (1) BR112015001106B1 (https=)
CA (1) CA2879238C (https=)
CY (1) CY2022018I1 (https=)
DK (1) DK2872487T3 (https=)
ES (1) ES2631655T3 (https=)
HU (2) HUE034409T2 (https=)
IL (1) IL236625B (https=)
IN (1) IN2015KN00265A (https=)
MX (1) MX350922B (https=)
MY (1) MY171483A (https=)
NZ (1) NZ704660A (https=)
PL (1) PL2872487T3 (https=)
PT (1) PT2872487T (https=)
SG (1) SG11201500234YA (https=)
WO (1) WO2014014834A1 (https=)
ZA (1) ZA201500664B (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2528232C (en) 2003-06-06 2010-05-25 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
WO2010056767A1 (en) 2008-11-14 2010-05-20 Fibrogen, Inc. Thiochromene derivatives as hip hydroxylase inhibitors
KR20210130849A (ko) * 2012-07-16 2021-11-01 피브로겐, 인크. 프롤릴 하이드록실라제 억제제 [(4-하이드록시-1-메틸-7-페녹시-아이소퀴놀린-3-카보닐)-아미노]-아세트산의 결정형
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
EP2872487B1 (en) 2012-07-16 2017-04-26 Fibrogen, Inc. Process for making isoquinoline compounds
KR20210104173A (ko) 2013-06-06 2021-08-24 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형
CN103694172A (zh) * 2013-12-26 2014-04-02 辽宁亿灵科创生物医药科技有限公司 含氮杂芳基化合物的衍生物
JP6506390B2 (ja) 2014-09-02 2019-04-24 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． キノリノン系化合物及びその薬物への使用
WO2016045125A1 (en) * 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
CN104447547B (zh) * 2014-11-10 2017-04-19 苏州康润医药有限公司 4‑氨基异喹啉‑8‑甲酸甲酯的合成方法
CN106146490B (zh) * 2015-03-27 2018-10-23 沈阳三生制药有限责任公司 被芳氧基或杂芳氧基取代的5-羟基-1,7-萘啶化合物、其制备方法及其制药用途
CN104892509B (zh) * 2015-06-04 2018-03-09 苏州明锐医药科技有限公司 诺得司他的制备方法
CN106187888A (zh) * 2016-07-18 2016-12-07 江苏德源药业股份有限公司 Fg‑4592单晶及其制备方法
CN106478503A (zh) * 2016-09-29 2017-03-08 上海勋和医药科技有限公司 Roxadustat中间体的制备方法
CZ2016627A3 (cs) 2016-10-07 2018-04-18 Zentiva, K.S. Způsob přípravy (7-fenoxy-4-hydroxy-1-methylisochinolin-3-karbonyl)glycinu (roxadustatu) a jeho intermediátů založený na souběžném otevírání oxazolového kruhu, štěpení etheru a tvorbě iminu
CN107954931B (zh) * 2016-10-17 2021-06-22 上海医药集团青岛国风药业股份有限公司 一种诺得司他的制备方法
CN110225753B (zh) * 2017-01-28 2022-12-09 金凯(辽宁)生命科技股份有限公司 用于制备5-苯氧基-1(3h)异苯并呋喃酮的方法
CA3083672A1 (en) * 2017-12-01 2019-06-06 Dr. Reddy's Laboratories Limited Process for the preparation of roxadustat and its intermediates
CN109956870A (zh) * 2017-12-14 2019-07-02 南京卡文迪许生物工程技术有限公司 一种罗沙司他的合成方法及其中间体化合物
CN110218184B (zh) * 2018-03-01 2022-09-27 广东东阳光药业有限公司 诺德司他共晶及其制备方法
CN115246789B (zh) * 2018-03-16 2023-10-17 上海医药集团青岛国风药业股份有限公司 一种诺得司他的制备方法
CN110526813B (zh) * 2018-05-24 2022-06-28 杭州科巢生物科技有限公司 异喹啉化合物的制备方法及其中间体
WO2019233321A1 (zh) 2018-06-05 2019-12-12 沈阳化工大学 一种三氟乙基硫醚(亚砜)取代苯类化合物及其用途
CA3118752A1 (en) 2018-11-09 2020-05-14 Vivace Therapeutics, Inc. Bicyclic compounds
CN109776415B (zh) * 2019-03-07 2020-11-17 福建南方制药股份有限公司 一种Roxadustat中间体的制备方法
HUE070525T2 (hu) 2019-04-16 2025-06-28 Vivace Therapeutics Inc Biciklusos vegyületek
RU2709493C1 (ru) * 2019-08-01 2019-12-18 Марат Феликсович Фазылов Способ получения роксадустата
US20220340532A1 (en) 2019-08-07 2022-10-27 Teva Pharmaceuticals International Gmbh Processes for the preparation of roxadustat and intermediates thereof
CN112441975B (zh) * 2019-09-03 2023-10-31 西藏嘉信景天药业有限公司 一种罗沙司他重要中间体的制备方法
CN112679430B (zh) * 2019-10-18 2023-05-05 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
CN112679431B (zh) * 2019-10-18 2023-05-05 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
WO2021073623A1 (zh) * 2019-10-18 2021-04-22 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
CN113444042A (zh) * 2020-03-27 2021-09-28 南京海润医药有限公司 一种罗沙司他的制备方法
CN115867537A (zh) * 2020-04-21 2023-03-28 迈兰实验室有限公司 改进的罗沙司他的制备方法
CN111533691A (zh) * 2020-06-08 2020-08-14 重庆三圣实业股份有限公司 一种罗沙司他的制备方法
CN113801060B (zh) * 2020-06-13 2025-06-27 苏州鹏旭医药科技有限公司 一种多取代异喹啉化合物的制备方法
EP4169906B1 (en) * 2020-06-19 2024-09-04 Jumpcan (Shanghai) Medical Technology Co., Ltd Method for synthesis of roxadustat and intermediate thereof, and intermediate thereof
CN112409258B (zh) * 2020-11-20 2025-11-25 杭州科巢生物科技有限公司 一种罗沙司他的制备方法
CN114644589A (zh) * 2020-12-17 2022-06-21 鲁南制药集团股份有限公司 一种化合物n-[（4-羟基--1-甲基-3-异喹啉基）羰基]-甘氨酸的制备方法
CN114671807B (zh) * 2020-12-24 2026-03-24 联化科技（德州）有限公司 一种1-取代异喹啉类化合物的制备方法
US20230101768A1 (en) * 2021-08-13 2023-03-30 The Board Of Regents Of The University Of Texas System Method to treat manganese toxicity and manganese-induced parkinsonism in humans
CN116178260A (zh) * 2021-11-26 2023-05-30 四川国康药业有限公司 一种治疗肾性贫血的化合物及其制备方法
CN115124467A (zh) * 2022-07-11 2022-09-30 天津力生制药股份有限公司 一种罗沙司他关键中间体的制备方法
CN117105862B (zh) * 2023-07-26 2025-12-30 北京福元医药股份有限公司 一种罗沙司他及其中间体的制备方法
CN117486797A (zh) * 2023-11-23 2024-02-02 传健生物医药(厦门)有限公司 一种罗沙司他关键中间体及罗沙司他的制备方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036964A (en) 1973-10-11 1977-07-19 Beecham Group Limited Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis
US3989704A (en) 1973-10-30 1976-11-02 Sandoz, Inc. 3-Substituted-4-aryl isoquinolines
DE2818423A1 (de) 1978-04-27 1979-11-08 Hoechst Ag Neue isochinolinderivate und verfahren zu ihrer herstellung
DE3233424A1 (de) 1982-09-09 1984-03-15 Hoechst Ag, 6230 Frankfurt Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4558006A (en) 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
US4559403A (en) 1983-05-19 1985-12-17 Hoffmann-La Roche Inc. Substituted isoquinolines
US4584379A (en) 1985-01-22 1986-04-22 Merrell Dow Pharmaceuticals Inc. Isoquinoline thromboxane synthetase inhibitors
US4667016A (en) 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
US4822800A (en) 1986-06-09 1989-04-18 Ortho Pharmaceutical Corporation Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
US4966906A (en) 1987-11-27 1990-10-30 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-isoquinolinecarboxamides
US4952588A (en) 1987-11-27 1990-08-28 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides
EP0650961B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
ES2101420T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
AU4515696A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
WO1998023608A1 (en) 1996-11-27 1998-06-04 Dupont Pharmaceuticals Company Novel integrin receptor antagonists
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
FR2779963A1 (fr) 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
IT1302677B1 (it) 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
WO2000064877A1 (en) 1999-04-26 2000-11-02 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
IT1320162B1 (it) 2000-02-09 2003-11-18 Rotta Research Lab Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
FI20002044A0 (fi) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
JP4590157B2 (ja) 2001-03-21 2010-12-01 アイシス イノヴェイション リミテッド アッセイ、方法および手段
GB0107901D0 (en) * 2001-03-29 2001-05-23 Cyclacel Ltd Anti-cancer compounds
US6716866B2 (en) 2001-06-13 2004-04-06 Genesoft Pharmaceuticals, Inc. Aryl-benzimidazole compounds having antiinfective activity
US6777425B2 (en) 2001-06-13 2004-08-17 Genesoft Pharmaceuticals, Inc. Isoquinoline compounds having antiinfective activity
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
CN102552263A (zh) 2001-12-06 2012-07-11 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
US8318703B2 (en) 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
WO2005007192A2 (en) 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
CA2528232C (en) * 2003-06-06 2010-05-25 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
CN100418948C (zh) 2003-07-15 2008-09-17 麦克公司 羟基吡啶cgrp受体抗拮抗剂
WO2005011696A1 (en) 2003-08-01 2005-02-10 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
WO2005014533A2 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
DE602005016800D1 (de) 2004-05-28 2009-11-05 Fibrogen Inc Hif-prolylhydroxylase-aktivitätstest
AP2007004047A0 (en) * 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
WO2006094292A2 (en) 2005-03-02 2006-09-08 Fibrogen, Inc. Thienopyridine compounds, and methods of use thereof
US20060276477A1 (en) 2005-06-06 2006-12-07 Fibrogen, Inc. Treatment method for anemia
AU2006259352A1 (en) 2005-06-15 2006-12-28 Fibrogen, Inc. Use of HIF 1alfa modulators for treatment of cancer
US7660800B2 (en) * 2005-11-28 2010-02-09 Commvault Systems, Inc. Systems and methods for classifying and transferring information in a storage network
EP2476669A1 (en) 2006-01-27 2012-07-18 Fibrogen, Inc. Cyanoisoquinoline compounds and methods of use thereof
US20070259960A1 (en) 2006-02-16 2007-11-08 Fibrogen, Inc. Compounds and methods for treatment of stroke
CN103497184A (zh) 2006-04-04 2014-01-08 菲布罗根有限公司 作为hif调节剂的吡咯并吡啶和噻唑并吡啶化合物
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
EP2334682B1 (en) 2008-08-20 2017-10-04 Fibrogen, Inc. Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators
WO2010056767A1 (en) 2008-11-14 2010-05-20 Fibrogen, Inc. Thiochromene derivatives as hip hydroxylase inhibitors
WO2012097331A1 (en) 2011-01-13 2012-07-19 Fibrogen, Inc. Methods for increasing reticulocyte hemoglobin content
CN103608346B (zh) 2011-02-02 2016-06-15 菲布罗根有限公司 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物
US9206134B2 (en) * 2011-07-22 2015-12-08 Beijing Betta Pharmaceuticals Co. Ltd. Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
AU2013229922B2 (en) 2012-03-09 2017-09-28 Kyntra Bio, Inc. 4 -hydroxy- isoquinoline compounds as HIF hydroxylase inhibitors
KR20210130849A (ko) 2012-07-16 2021-11-01 피브로겐, 인크. 프롤릴 하이드록실라제 억제제 [(4-하이드록시-1-메틸-7-페녹시-아이소퀴놀린-3-카보닐)-아미노]-아세트산의 결정형
EP2872487B1 (en) 2012-07-16 2017-04-26 Fibrogen, Inc. Process for making isoquinoline compounds
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
CA2899024C (en) 2013-01-24 2022-01-04 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
KR20210104173A (ko) 2013-06-06 2021-08-24 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형

Also Published As

Publication number Publication date
CY2022018I2 (el) 2023-01-05
IN2015KN00265A (https=) 2015-06-12
EP2872487A1 (en) 2015-05-20
CA2879238A1 (en) 2014-01-23
JP2015524409A (ja) 2015-08-24
CN103435546B (zh) 2016-08-10
US9340511B2 (en) 2016-05-17
KR102145272B1 (ko) 2020-08-18
NZ704660A (en) 2017-10-27
JP6196671B2 (ja) 2017-09-13
BR112015001106A2 (pt) 2017-06-27
CN106083719B (zh) 2019-10-18
HUS2200030I1 (hu) 2022-07-28
MX2015000505A (es) 2015-07-17
HUE034409T2 (en) 2018-02-28
ES2631655T3 (es) 2017-09-01
DK2872487T3 (en) 2017-06-06
BR112015001106B1 (pt) 2021-11-09
WO2014014834A1 (en) 2014-01-23
ZA201500664B (en) 2017-08-30
AU2013290437A1 (en) 2015-02-19
CY2022018I1 (el) 2023-01-05
KR20150058147A (ko) 2015-05-28
EP3219706A1 (en) 2017-09-20
US20160194285A1 (en) 2016-07-07
PL2872487T3 (pl) 2017-09-29
IL236625A0 (en) 2015-02-26
PT2872487T (pt) 2017-05-15
US20150175550A1 (en) 2015-06-25
EP2872487B1 (en) 2017-04-26
IL236625B (en) 2019-01-31
CN106083719A (zh) 2016-11-09
CN103435546A (zh) 2013-12-11
MX350922B (es) 2017-09-25
US9708269B2 (en) 2017-07-18
AU2013290437B2 (en) 2017-11-02
CA2879238C (en) 2021-08-10
MY171483A (en) 2019-10-15

Similar Documents

Publication Publication Date Title
ZA201500664B (en) Process for making isoquinoline compounds
GB201216921D0 (en) Process
GB201207997D0 (en) Process
GB201214326D0 (en) Process
ZA201408399B (en) Hydroformylation process
GB201500761D0 (en) Process
ZA201409261B (en) Process for making hydroxylated cyclopentylpyrimidine compounds
IL235714A0 (en) A process for preparing hydroxylated cyclopentylpyrimidine compounds
GB201219224D0 (en) Process
PT2914574T (pt) Processo novo
GB201318062D0 (en) Process
EP2852660A4 (en) PROCESS
IL233433A0 (en) A process for preparing affluents
GB201317561D0 (en) Process
GB201316604D0 (en) Process
HUP1200614A2 (en) Process for development catalayzer
GB201220666D0 (en) Process for preparing chemical compounds
GB201209932D0 (en) Improved process
GB201202098D0 (en) New process
GB201223071D0 (en) Process
GB201222686D0 (en) Process
GB201220746D0 (en) Process
GB201220610D0 (en) Process
GB201218576D0 (en) Process
GB201215646D0 (en) Process